Thursday, June 6, 2024
8 am PT, 11 am ET, 17:00 CET
View the recording
Assessment of antibody off-target reactivity is a regulatory requirement for clinical development. However, conventional screening methods, such as tissue cross-reactivity studies, are often ineffective in screening newer therapeutic modalities, and their predictive value for in vivo safety and toxicity is poor. So, what are the alternatives?
Join our webinar to learn about the new, innovative cell-based protein array approach to specificity profiling. We’ll take a deep dive into the Membrane Proteome Array (MPA), a 6,000-protein array platform that tests binding of biotherapeutics across the full human membrane proteome expressed in unfixed cells.
Attendees will learn how:
- Integral Molecular’s MPA is used to rapidly and accurately identify potential off-target binding liabilities
- MPA data support both lead selection and IND submissions with advantages over tissue cross-reactivity studies
- Cell protein arrays, like the MPA, are rapidly progressing towards FDA endorsement through inclusion in CAR-T development guidelines and qualification as an antibody Drug Development Tool
